.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL04_IndacaterolAndGlycopyrroniumBrom.IndacaterolAndGlycopyrroniumBrom

Information

Indacaterol and glycopyrronium bromide, under the ATC code R03AL04, is a fixed-dose combination inhalation therapy used in the treatment of chronic obstructive pulmonary disease (COPD) to improve lung function and reduce exacerbations. Indacaterol is a long-acting beta2-adrenergic agonist (LABA), while glycopyrronium is a long-acting muscarinic antagonist (LAMA). The combination is approved and in use for maintenance treatment of COPD in adults.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects following inhalation. Parameters refer to steady-state or single-dose studies. Both drugs are administered together via inhalation in a fixed-dose combination.

References

1. Demin, I, et al., & Sechaud, R (2016). Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients. International journal of clinical pharmacology and therapeutics 54(6) 405–415. DOI:10.5414/CP202558 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27049057

2. Ren, S, et al., & Zhao, R (2017). Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
. International journal of clinical pharmacology and therapeutics 55(2) 147–155. DOI:10.5414/CP202640 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27841152

3. Inoue, S, et al., & Furihata, K (2021). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC pulmonary medicine 21(1) 18–None. DOI:10.1186/s12890-020-01382-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33413291

Revisions

• 06/2025 initial generated model